Literature DB >> 28286152

Toxin production of Clostridium difficile in sub-MIC of vancomycin and clindamycin alone and in combination with ceftazidime.

Ebrahim Rezazadeh Zarandi1, Shahla Mansouri1, Nouzar Nakhaee2, Farhad Sarafzadeh3, Mohammad Moradi4.   

Abstract

Toxin production in Clostridium difficile (C. difficile) is a key process for induction of diarrhea. Several factors such as sub-MIC of antibiotics impact on toxin production. The aim of this research is investigation of sub-minimum inhibitory concentration (sub-MIC) of vancomycin (VAN), clindamycin (CLI) separately and in combination with ceftazidime (CAZ) on toxin production in C. difficile. About ∼106 colony forming units (CFU) from 18-h culture of C. difficile ATCC 9689 and clinical isolates A+/B+/CTD-, were cultured anaerobically in the pre-reduced medium with appropriate concentration of separated and in combination antibiotics. After 24 and 48 h, 1 mL of culture was removed, centrifuged and the supernatant stored at-70 °C for later use. The evaluation of toxin production was carried out by the ELISA technique. All antibiotics alone and in combination formats inhibited toxin production over a period of 24 h. This effect is also observed in presence of VAN and CLI during a period of 48 h. Over a 4 h period, CAZ increased toxin production alone and in combination, especially with CLI. The data showed VAN and CLI decrease the level of toxins. In contrast, the CAZ not only increases the level of produced toxin, but also can interfere with VAN and CLI. Based on the results, combination therapy which is performed for treatment or prevention of other infections may cause toxin production and probably the severity of C. difficile AAD to increase.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; Clostridium difficile; Combination; Toxin production

Mesh:

Substances:

Year:  2017        PMID: 28286152     DOI: 10.1016/j.micpath.2017.03.002

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

1.  In vivo commensal control of Clostridioides difficile virulence.

Authors:  Brintha P Girinathan; Nicholas DiBenedetto; Jay N Worley; Johann Peltier; Mario L Arrieta-Ortiz; Selva Rupa Christinal Immanuel; Richard Lavin; Mary L Delaney; Christopher K Cummins; Maria Hoffman; Yan Luo; Narjol Gonzalez-Escalona; Marc Allard; Andrew B Onderdonk; Georg K Gerber; Abraham L Sonenshein; Nitin S Baliga; Bruno Dupuy; Lynn Bry
Journal:  Cell Host Microbe       Date:  2021-10-11       Impact factor: 21.023

2.  Antibacterial Activity of Bifidobacterium breve Against Clostridioides difficile.

Authors:  Jingpeng Yang; Hong Yang
Journal:  Front Cell Infect Microbiol       Date:  2019-08-07       Impact factor: 5.293

3.  Toxin A and B genes expression of Clostridium difficile in the sub-minimum inhibitory concentration of clindamycin, vancomycin and in combination with ceftazidime.

Authors:  Mohammad Moradi; Shahla Mansouri; Nouzar Nakhaee; Farhad Sarafzadeh; Ebrahim Rezazadeh Zarandi
Journal:  Iran J Microbiol       Date:  2020-02

Review 4.  Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus.

Authors:  Anders F Johnson; Christopher N LaRock
Journal:  Front Microbiol       Date:  2021-11-04       Impact factor: 5.640

5.  Sub-Inhibitory Concentrations of Amoxicillin and Tylosin Affect the Biofilm Formation and Virulence of Streptococcus suis.

Authors:  Jing Zuo; Qingying Fan; Jinpeng Li; Baobao Liu; Bingqian Xue; Xiaoling Zhang; Li Yi; Yang Wang
Journal:  Int J Environ Res Public Health       Date:  2022-07-08       Impact factor: 4.614

6.  Evaluation of Derivatives of (+)-Puupehenone against Clostridioides difficile and Other Gram-Positive Bacteria.

Authors:  Michael A Johnstone; Alexander D Landgraf; Anshupriya Si; Steven J Sucheck; William T Self
Journal:  ACS Omega       Date:  2022-09-09

7.  Frequency of antibiotic associated diarrhea caused by Clostridium difficile among hospitalized patients in intensive care unit, Kerman, Iran.

Authors:  Ebrahim Rezazadeh Zarandi; Shahla Mansouri; Nouzar Nakhaee; Farhad Sarafzadeh; Zahra Iranmanesh; Mohammad Moradi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.